Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-26T23:07:24.323Z Has data issue: false hasContentIssue false
  • English
  • Français

Occlutech® muscular ventricular septal defect device: the first reported human use

Published online by Cambridge University Press:  22 June 2016

Gareth J. Morgan
Gareth J. Morgan*
Affiliation:
Department of Congenital Cardiology, Guys and St Thomas’ NHS Foundation Trust, Kings College London, London, United Kingdom
*
Correspondence to: Dr G. J. Morgan, MB, BaO, BCh, MPhil, MRCPCH, Department of Congenital Cardiology, Guys and St Thomas’ NHS Foundation Trust, Westminster Bridge Road, London SE1 7EH, United Kingdom. Tel:+4 420 7188 9617; Fax:+4 420 7188 4556; E-mail: drgarethjmorgan@gmail.com
Get access Rights & Permissions [Opens in a new window]

Abstract

Percutaneous closure of muscular ventricular septal defects has been well described and has not attracted the same controversy or scrutiny as perimembranous defect closure. Therefore, the development of specifically designed devices has been limited. We report the first use of the Occlutech® muscular ventricular septal defect device. Does its design add any significant benefit?

Keywords

Percutaneousclosuredevice developmentinterventional cardiology
Type
Brief Reports
Information
Cardiology in the Young , Volume 26 , Issue 7 , October 2016 , pp. 1448 - 1451
Check for updates
Copyright
© Cambridge University Press 2016 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Cantinotti, M, Assanta, N, Murzi, B, Lopez, L. Controversies in the definition and management of insignificant left-to-right shunts. Heart 2014; 100: 200–205.Google Scholar
2. Carminatti, M, Buttera, G, Chessa, M, et al. Transcatheter closure of congenital ventricular septal defects: results of the European Registry. Eur Heart J 2007; 28: 2361–2368.Google Scholar
3. Haas, N, Happel, CM, Soetemann, DB, et al. Optimal septal alignment of the Figulla ® Flex occluder to the atrial septum in patients with secundum atrial septal defects. Eurointervention 2016; 11: 1153–1160.Google Scholar
4. Dankowski, R, Baszko, A, Sutherland, M, et al. 3D heart model printing for preparation of percutaneous structural interventions: description of the technology and case report. Kardiol Pol 2014; 72: 546–551.Google Scholar
5. Kenny, D, Morgan, G, Bajwa, A, et al. Evolution of transcatheter closure of perimembranous ventricular septal defects in a single centre. Catheter Cardiovasc Interv 2009; 73: 568–575.Google Scholar
6. Pedra, CA, Pedra, SF, Costa, RN, et al. Mid-term outcomes after percutaneous closure of the secundum atrial septal defect with the Figulla-Occlutech ® device. J Interv Cardiol 2016; 29: 208–215.Google Scholar
7. Zartner, P, Christians, C, Stelter, JC, Hraska, V, Schneider, MB. Transvascular closure of single and multiple muscular ventricular septal defects in neonates and infants <20kg. Catheter Cardiovasc Interv 2014; 83: 564–570.Google Scholar
8. Shibbani, K, Kenny, D, McElhnney, D, Hijazi, ZM, Moran, T. Identifying gaps in technology for congenital interventions: analysis of a needs survey from Congenital Interventional Cardiologists. Pediatr Cardiol 2016; 37: 925–931.Google Scholar